F G A van der Meche
Overview
Explore the profile of F G A van der Meche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janssens A, Buljevac D, van Doorn P, van der Meche F, Polman C, Passchier J, et al.
Mult Scler
. 2007 Feb;
12(6):794-801.
PMID: 17263009
Objective: To investigate the course of anxiety, depression and disease-related distress of patients with multiple sclerosis (MS) and their partners in the first years after diagnosis. Methods: The Hospital Anxiety...
2.
Garssen M, Schmitz P, Merkies I, Jacobs B, van der Meche F, van Doorn P
J Neurol Neurosurg Psychiatry
. 2005 Dec;
77(1):61-5.
PMID: 16361594
Objective: Fatigue is a major complaint in patients with immune mediated polyneuropathies. Despite apparently good physical recovery after Guillain-Barré syndrome (GBS), many patients remain restricted in daily and social activities,...
3.
Samijn J, Te Boekhorst P, Mondria T, van Doorn P, Flach H, van der Meche F, et al.
J Neurol Neurosurg Psychiatry
. 2005 Dec;
77(1):46-50.
PMID: 16361591
Background: Certain stem cell transplantation procedures might slow down inflammatory pathology in multiple sclerosis (MS). Aims: To halt disease progression in aggressive MS by a bone marrow transplantation (BMT) protocol...
4.
Buljevac D, van Doornum G, Flach H, Groen J, Osterhaus A, Hop W, et al.
J Neurol Neurosurg Psychiatry
. 2005 Sep;
76(10):1377-81.
PMID: 16170080
Objectives: To study in relapsing-remitting (RR) multiple sclerosis (MS) whether exacerbations and brain activity as measured by magnetic resonance imaging (MRI) are associated with plasma levels of anti-Epstein Barr (EBV)...
5.
Janssens A, van Doorn P, De Boer J, van der Meche F, Passchier J, Hintzen R
Acta Neurol Scand
. 2003 Nov;
108(6):389-95.
PMID: 14616290
Objectives: Studies demonstrating reduced quality of life and psychological well-being in multiple sclerosis (MS) have typically investigated patients within more advanced stages of disease. The aim of the present paper...
6.
Buljevac D, Hop W, Reedeker W, Janssens A, van der Meche F, van Doorn P, et al.
BMJ
. 2003 Sep;
327(7416):646.
PMID: 14500435
Objective: To study the relation between self reported stressful life events not related to multiple sclerosis and the occurrence of exacerbations in relapsing-remitting multiple sclerosis. Design: Longitudinal, prospective cohort study....
7.
Janssens A, van Doorn P, De Boer J, Kalkers N, van der Meche F, Passchier J, et al.
Mult Scler
. 2003 Aug;
9(4):397-403.
PMID: 12926846
Disability status, depression and anxiety are important determinants of quality of life (QoL) in patients with multiple sclerosis (MS). We investigated whether anxiety and depression influence the relation between disability...
8.
Merkies I, Schmitz P, van der Meche F, Samijn J, van Doorn P
J Neurol Neurosurg Psychiatry
. 2002 Dec;
74(1):99-104.
PMID: 12486276
Background: In the World Health Organisation (WHO) International Classification of Impairments, Disabilities, and Handicaps (ICIDH), it is suggested that various levels of outcome are associated with one another. However, the...
9.
Ang C, Tio-Gillen A, Groen J, Herbrink P, Jacobs B, van Koningsveld R, et al.
J Neuroimmunol
. 2002 Sep;
130(1-2):179-83.
PMID: 12225900
Anti-galactocerebroside (GalC) antibodies are reported to be present in GBS patients with preceding Mycoplasma pneumoniae (MP) infection. We investigated the presence of anti-GalC reactivity in serum of a large group...
10.
Merkies I, Schmitz P, van der Meche F, Samijn J, van Doorn P
Neurology
. 2002 Jul;
59(1):84-91.
PMID: 12105312
Objectives: To determine whether quality of life complements traditional outcome measures in immune-mediated polyneuropathies using the Medical Outcome Study 36-item short-form health status scale (SF-36). The validity, reliability, and responsiveness...